In our analysis, aside from trastuzumab, entrectinib showed the strongest association with CTRCD [ROR 10.84; 95% CI (7.24–16.24)], despite no specific cardiovascular assessment recommendations in the 2022 ESC Guidelines.9 Entrectinib, a multikinase inhibitor, was evaluated in a pooled safety analysis of 224 ROS1 fusion-positive non-small-cell lung cancer patients.18 Left ventricular ejection fraction reduction occurred in 1.3% of patients, and HF in 2.7%, mostly grade 3 or 4. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.